This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cynthia M. Stonnington, M.D., Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01780519
First received: January 29, 2013
Last updated: November 9, 2016
Last verified: November 2016
  Purpose
The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.

Condition Intervention Phase
Alzheimer's Disease (AD) Drug: lorazepam Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

Resource links provided by NLM:


Further study details as provided by Cynthia M. Stonnington, M.D., Mayo Clinic:

Primary Outcome Measures:
  • Groton Maze Learning Test (GMLT) score [ Time Frame: baseline to 5 hours ]
    The GMLT assesses visuospatial working memory, error monitoring, information processing speed, and short-term delayed recall for a complex hidden maze. Subjects are familiarized with the task during two untimed practice tests, and once the tester is confident that the subject understands the rules and can move easily around the grid, the timed test is administered. In each of the 5 successive trials of the GMLT exam, the subject is asked to learn to navigate his or her way around a 28-step maze that is hidden beneath a 10 x 10 grid of squares on the computer touch screen. For each trial, the time to completion, number of correct moves, number of wrong moves, and the number of perseverative errors are recorded.


Secondary Outcome Measures:
  • Auditory Verbal Learning Test (AVLT) Long-term memory score [ Time Frame: baseline to 5 hours ]
    The AVLT assesses verbal memory

  • Two Back Test (TBK) [ Time Frame: baseline to 5 hours ]
    The TBK measures working memory


Enrollment: 57
Study Start Date: January 2013
Study Completion Date: September 2016
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
L/VL APOE e3/e4 carrier
long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
Drug: lorazepam
single dose of 1 mg lorazepam
Other Name: Ativan
L/S APOE e3/e4 carrier
long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
Drug: lorazepam
single dose of 1 mg lorazepam
Other Name: Ativan
S/VL APOE e3/e3 carrier
short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
Drug: lorazepam
single dose of 1 mg lorazepam
Other Name: Ativan
VL/VL APOE e3/e3 carrier
Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
Drug: lorazepam
single dose of 1 mg lorazepam
Other Name: Ativan
S/S APOE e3/e3 carrier
short poly - T variants of TOMM40 and APOE e3/e3 carrier
Drug: lorazepam
single dose of 1 mg lorazepam
Other Name: Ativan

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Mini-Mental State Examination (MMSE) score of 28-30
  • Hamilton Depression Rating Scale score of less than 10
  • participants in longitudinal study of aging and have a TOMM40 genotype of S/S, VL/VL, S/VL, L/S or L/VL.

Exclusion criteria:

  • Alzheimer's Disease or Mild Cognitive Impairment
  • any significant medical, psychiatric, and neurological illnesses, e.g., impaired liver or kidney function, prior stroke, traumatic brain injury, memory impairment, cognitive impairment, parkinsonism, a lifetime history of schizophrenia, bipolar disorder, a psychoactive substance use disorder, or current major depression.
  • known allergy to benzodiazepines
  • current use (within the previous four weeks) of benzodiazepines or other medications known to interact with lorazepam, current use of sedating antihistamines, or current use of stimulant medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01780519

Locations
United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Cynthia Stonnington, MD Mayo Clinic
  More Information

Responsible Party: Cynthia M. Stonnington, M.D., PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01780519     History of Changes
Other Study ID Numbers: 12-006469
Study First Received: January 29, 2013
Last Updated: November 9, 2016

Keywords provided by Cynthia M. Stonnington, M.D., Mayo Clinic:
Alzheimer's disease (AD)

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Lorazepam
Anticonvulsants
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 28, 2017